Insulet Corporation (PODD) : Traders are bullish on Insulet Corporation (PODD) as it has outperformed the S&P 500 by a wide margin of 24.53% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.19%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.16% in the last 1 week, and is up 25.01% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Insulet Corporation is up 52.28% in the last 3-month period. Year-to-Date the stock performance stands at 15.02%. The stock has recorded a 20-day Moving Average of 9.68% and the 50-Day Moving Average is 26.15%.
Insulet Corporation (NASDAQ:PODD): The stock opened at $43.53 on Friday but the bulls could not build on the opening and the stock topped out at $43.83 for the day. The stock traded down to $42.86 during the day, due to lack of any buying support eventually closed down at $43.49 with a loss of -0.57% for the day. The stock had closed at $43.74 on the previous day. The total traded volume was 373,371 shares.
Also, Brokerage firm Jefferies maintains its rating on Insulet Corporation (NASDAQ:PODD). As per the latest information, the brokerage house raises the price target to $45 per share from a prior target of $41. The shares have been rated Buy. The rating by the firm was issued on August 4, 2016.
Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.